Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sørensen, T. L.
Right arrow Articles by Petersen, H. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sørensen, T. L.
Right arrow Articles by Petersen, H. C.
Neurology 1999;53:473
© 1999 American Academy of Neurology
Articles

Optic neuritis as onset manifestation of multiple sclerosis

A nationwide, long-term survey

T. L. Sørensen, MD, J. L. Frederiksen, MD, H. Brønnum-Hansen, MSc and H. C. Petersen, PhD

From the The MS Clinic, Department of Neurology (Drs. Sørensen and Frederiksen), University of Copenhagen, Glostrup Hospital; and the Danish Institute for Clinical Epidemiology (H. Brønnum-Hansen and Dr. Petersen), Copenhagen, Denmark.

Address correspondence and reprint requests to Dr. Torben Lykke Sørensen, The MS Clinic, Department of Neurology, University of Copenhagen, Glostrup Hospital, DK-2600 Glostrup, Denmark.

OBJECTIVE: To determine the predictive value on survival of optic neuritis (ON) as onset manifestation of MS.

METHODS: We used data obtained from the Danish Multiple Sclerosis Registry, which includes virtually all patients diagnosed with MS in Denmark. From 1949 to 1990, 7,548 unselected patients fulfilling standardized diagnostic criteria of MS were registered.

RESULTS: The onset manifestation of MS was known in 6,923 patients, and was ON in 1,282 patients (19%). The mean age at onset was 31.1 years for these patients compared with 34.8 years for patients with another or unknown onset manifestation of MS (non-ON) (p < 0.001). The mean delay from the first known manifestation of MS to the final diagnosis of MS was 6.1 years (ON) and 4.2 years (non-ON). The median survival time from onset of ON was 30 years in men (compared with 41 years in the matched general male population) and 40 years in women (versus 47 years). The excess death rate increased with age at onset of MS in people of each sex. Excess death rate for women differed significantly between patients with ON as onset manifestation and patients with another or unknown onset manifestation of MS (8.3 versus 13.0). In patients with ON as onset manifestation of MS, the excess death rate was significantly higher in men (14.0) than in women (8.3).

CONCLUSION: ON as onset manifestation of MS indicates a more favorable prognosis of survival of MS judged by excess death rate only in women.




This article has been cited by other articles:


Home page
 IOVSHome page
H. Merle, S. Olindo, A. Donnio, R. Richer, D. Smadja, and P. Cabre
Retinal Peripapillary Nerve Fiber Layer Thickness in Neuromyelitis Optica
Invest. Ophthalmol. Vis. Sci., October 1, 2008; 49(10): 4412 - 4417.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
F. C. Gundogan, S. Demirkaya, and G. Sobaci
Is Optical Coherence Tomography Really a New Biomarker Candidate in Multiple Sclerosis? A Structural and Functional Evaluation
Invest. Ophthalmol. Vis. Sci., December 1, 2007; 48(12): 5773 - 5781.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
K. Korsholm, K. H. Madsen, J. L. Frederiksen, A. Skimminge, and T. E. Lund
Recovery from optic neuritis: an ROI-based analysis of LGN and visual cortical areas
Brain, May 1, 2007; 130(5): 1244 - 1253.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. J. Balcer, S. L. Galetta, P. A. Calabresi, C. Confavreux, G. Giovannoni, E. Havrdova, M. Hutchinson, L. Kappos, F. D. Lublin, D. H. Miller, et al.
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis
Neurology, April 17, 2007; 68(16): 1299 - 1304.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
S Sotgiu, G Arru, M Soderstrom, G Mameli, C Serra, and A Dolei
Multiple sclerosis-associated retrovirus and optic neuritis
Multiple Sclerosis, June 1, 2006; 12(3): 357 - 359.
[Abstract] [PDF]

Home page
 Mult SclerHome page
M Pinholt, J L Frederiksen, P S Andersen, and M Christiansen
Apo E in multiple sclerosis and optic neuritis: the Apo E-o4 allele is associated with progression of multiple sclerosis
Multiple Sclerosis, October 1, 2005; 11(5): 511 - 515.
[Abstract] [PDF]

Home page
 Br. J. Ophthalmol.Home page
T L Sorensen, H Roed, and F Sellebjerg
Optic neuritis: chemokine receptor CXCR3 and its ligands
Br. J. Ophthalmol., September 1, 2004; 88(9): 1146 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
Y P Jin, J de Pedro-Cuesta, Y H Huang, and M Soderstrom
Predicting multiple sclerosis at optic neuritis onset
Multiple Sclerosis, April 1, 2003; 9(2): 135 - 141.
[Abstract] [PDF]

Home page
 Mult SclerHome page
L. J Balcer, M. L Baier, A. M Kunkle, R. A Rudick, B. Weinstock-Guttman, N. Simonian, S. L Galetta, G. R Cutter, and M. G Maguire
Self-reported visual dysfunction in multiple sclerosis: results from the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25)
Multiple Sclerosis, December 1, 2000; 6(6): 382 - 385.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.